{"id":924735,"date":"2026-01-07T07:52:18","date_gmt":"2026-01-07T12:52:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/"},"modified":"2026-01-07T07:52:18","modified_gmt":"2026-01-07T12:52:18","slug":"palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/","title":{"rendered":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs"},"content":{"rendered":"
\n

\n Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n , povorcitinib, ILUMYA\u00ae, ODOMZO<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n , REMICADE<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n , and STELARA<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>\n <\/p>\n

\n Dr. Patel to lead Palvella\u2019s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company\u2019s QTORIN\u2122 programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations<\/em>\n <\/p>\n

WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA<\/a>) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the appointment of Vimal Patel, PharmD, as Senior Vice President of Medical Affairs. Dr. Patel brings more than 25 years of medical affairs leadership experience across dermatology and immunology with deep experience supporting late-stage development, commercial launches, and product lifecycle management.<\/p>\n

\u201cVimal brings decades of medical affairs leadership experience, deep dermatology expertise, and a strong track record advancing innovative therapies to patients,\u201d said Wes Kaupinen, Founder and CEO of Palvella. \u201cHe brings the energy and leadership needed to ensure our QTORIN\u2122 programs remain guided by rigorous science and thoughtful medical strategy as we advance targeted therapies for serious, rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations. Vimal\u2019s experience supporting late-stage development and commercial launches, along with his success building best-in-class Medical Affairs organizations and long-standing relationships across the dermatology and rare disease medical community, will be integral as we lay the foundation for near-term potential QTORIN\u2122 launches and continue to expand our rare disease pipeline.\u201d<\/p>\n

Prior to joining Palvella, Dr. Patel served as Dermatology Therapeutic Area Head, Medical Affairs at Incyte, where he led medical strategy across atopic dermatitis, vitiligo, and hidradenitis suppurativa. In this role, he oversaw evidence generation, medical education, insights, and field medical execution. During his tenure, he played a key role in supporting the introduction and advancement of innovative dermatology therapies, including OPZELURA\u00ae<\/sup> and povorcitinib, and held multiple leadership roles, including National Director of Field Medical Affairs and Executive Director of Medical Affairs.<\/p>\n

Prior to Incyte, Dr. Patel held senior leadership roles at Sun Pharma, where he served as Head of Medical Sales Liaisons and Medical Information for North America for ILUMYA\u00ae and Global Commercialization Lead for ODOMZO\u00ae, leading global asset integration and launch readiness. Earlier in his career, he spent nearly 15 years at Johnson & Johnson, holding roles across medical information, accredited medical education, field leadership, and brand strategy, contributing to the success of multiple high-impact immunology and dermatology therapies, including REMICADE\u00ae<\/sup> and STELARA\u00ae<\/sup>. Dr. Patel holds a Bachelor of Science and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy.<\/p>\n

\u201cPalvella represents a compelling, mission-driven company developing much-needed, innovative therapies for patients living with serious, rare skin diseases for which no FDA-approved treatment options exist,\u201d said Dr. Patel. \u201cPalvella\u2019s patient-first approach and the commitment of the Company\u2019s leadership team to build the leading rare disease company focused on serious, rare skin diseases strongly resonate with me. Through my experience in dermatology, I have seen firsthand the magnitude of unmet need across rare disease patient communities, which reinforces the importance of advancing rigorous science, building strong clinical evidence, and engaging the medical community to ultimately improve patient outcomes. QTORIN\u2122 represents a pioneering platform with the potential to transform the treatment paradigm for many rare skin diseases by enabling targeted therapies designed to address the underlying pathobiology of those diseases, and I am particularly excited to contribute to the development and potential near-term launch of innovative QTORIN\u2122 programs.\u201d<\/p>\n

\n About Palvella Therapeutics<\/strong>\n <\/p>\n

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN\u2122 platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN\u2122 3.9% rapamycin anhydrous gel (QTORIN\u2122 rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella\u2019s second product candidate, QTORIN\u2122 pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis. For more information, please visit\u00a0www.palvellatx.com<\/u><\/a>\u00a0or follow Palvella on\u00a0LinkedIn<\/u><\/a>\u00a0or\u00a0X<\/u><\/a>\u00a0(formerly known as Twitter).<\/p>\n

QTORIN\u2122 rapamycin and QTORIN\u2122 pitavastatin are for investigational use only and neither has been approved or cleared by the FDA or by any other regulatory agency for any indication.<\/p>\n

\n Forward-Looking Statements<\/strong><\/p>\n

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Palvella\u2019s clinical development plans and related anticipated development milestones, Palvella\u2019s cash, financial resources and expected runway, Palvella\u2019s expectations regarding its programs, including QTORIN\u2122 rapamycin and QTORIN\u2122 pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella\u2019s product candidates, including QTORIN\u2122 rapamycin and QTORIN\u2122 pitavastatin; the outcome of early clinical trials for Palvella\u2019s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella\u2019s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella\u2019s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.<\/p>\n

\n Contact\u00a0Information<\/strong>\n <\/p>\n

\n Investors<\/u>
\n
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com<\/u><\/a><\/p>\n

\n Media<\/u>
\n
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA \u00ae , povorcitinib, ILUMYA\u00ae, ODOMZO \u00ae , REMICADE \u00ae , and STELARA \u00ae Dr. Patel to lead Palvella\u2019s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company\u2019s QTORIN\u2122 programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced … <\/p>\n

Continue reading “Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924735","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPalvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA \u00ae , povorcitinib, ILUMYA\u00ae, ODOMZO \u00ae , REMICADE \u00ae , and STELARA \u00ae Dr. Patel to lead Palvella\u2019s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company\u2019s QTORIN\u2122 programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced … Continue reading "Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T12:52:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs\",\"datePublished\":\"2026-01-07T12:52:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/\"},\"wordCount\":1441,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/\",\"name\":\"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=\",\"datePublished\":\"2026-01-07T12:52:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk","og_description":"Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA \u00ae , povorcitinib, ILUMYA\u00ae, ODOMZO \u00ae , REMICADE \u00ae , and STELARA \u00ae Dr. Patel to lead Palvella\u2019s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company\u2019s QTORIN\u2122 programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced … Continue reading \"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T12:52:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs","datePublished":"2026-01-07T12:52:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/"},"wordCount":1441,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/","name":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=","datePublished":"2026-01-07T12:52:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTIxNiM3MzQ4MzA0IzIxMjMxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-medical-affairs-leader-vimal-patel-pharmd-as-senior-vice-president-of-medical-affairs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924735"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}